Jefferies Financial Group Weighs in on Roche Holdings AG Basel ADR’s FY2021 Earnings (OTCMKTS:RHHBY)
Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) – Equities researchers at Jefferies Financial Group upped their FY2021 EPS estimates for Roche Holdings AG Basel in a research report issued on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of $2.62 for the year, up from their previous forecast of $2.57. Jefferies Financial Group also issued estimates for Roche Holdings AG Basel’s FY2022 earnings at $2.74 EPS and FY2023 earnings at $2.98 EPS.
Other analysts have also issued reports about the company. Zacks Investment Research upgraded DLH from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th. Deutsche Bank reiterated a “buy” rating and set a GBX 2,450 ($32.01) price target on shares of in a report on Thursday, June 20th. Finally, Liberum Capital reiterated a “buy” rating and set a GBX 525 ($6.86) price target on shares of in a report on Thursday, June 20th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $35.50.
Institutional investors have recently modified their holdings of the stock. Advisors Asset Management Inc. bought a new stake in Roche Holdings AG Basel during the first quarter worth $144,000. Beck Mack & Oliver LLC bought a new stake in Roche Holdings AG Basel during the first quarter worth $203,000. South Texas Money Management Ltd. bought a new stake in Roche Holdings AG Basel during the first quarter worth $215,000. MAI Capital Management bought a new stake in Roche Holdings AG Basel during the first quarter worth $220,000. Finally, Dearborn Partners LLC increased its position in Roche Holdings AG Basel by 11.9% in the first quarter. Dearborn Partners LLC now owns 9,339 shares of the company’s stock worth $321,000 after buying an additional 992 shares during the last quarter. Institutional investors and hedge funds own 0.30% of the company’s stock.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Read More: CD Ladder
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.